Literature DB >> 27416564

Early onset pancreatic malignancies: Clinical characteristics and survival associations.

Alicia Beeghly-Fadiel1, Hung N Luu1,2, Liping Du3, Chanjuan Shi4, Dauphne P McGavic5, Alexander A Parikh6, Leon Raskin7.   

Abstract

Diagnosed before age 50, early onset pancreatic malignancy (EOPM), is hypothesized to be a distinct subset of disease, although research is limited. To better characterize EOPM, and the effect of age at diagnosis on pancreatic cancer survival, we examined clinical characteristics and survival in EOPM and typical age-at-onset pancreatic malignancy (TOPM) cases. Vanderbilt University Medical Center (VUMC) Cancer Registry confirmed pancreatic adenocarcinomas (PDACs) and malignant pancreatic neuroendocrine tumors (PNETs) were evaluated. Clinical characteristics were compared using χ(2) tests. Overall survival was visualized with Kaplan-Meier functions; Cox proportional hazards regression was used to evaluate hazard ratios (HRs) and 95% confidence intervals (CIs). A total of 1,697 pancreatic malignancies were diagnosed at the VUMC between 1988 and 2013. Of 1,407 PDACs, 118 (8.4%) were EOPM, which was associated with significantly better survival (adjusted HR: 0.82, 95% CI: 0.67-1.00). EOPM and TOPM PDACs significantly differed with regard to having multiple malignancies; survival associations significantly differed by race, stage of disease, treatment and multiple malignancies. Of 190 PNETs, 63 (33.1%) were EOPM, which was not significantly associated with survival (adjusted HR: 0.80, 95% CI: 0.46-1.40). Malignant neuroendocrine EOPM and TOPM cases significantly differed by stage of disease and tumor location; survival associations significantly differed by family history of pancreatic cancer, stage of disease and multiple malignancies. Differences in clinical characteristics and associations with survival were identified, indicating that EOPM is distinct from TOPM, and exists among both pancreatic adenocarcinomas and malignant pancreatic neuroendocrine tumors.
© 2016 UICC.

Entities:  

Keywords:  PDAC; PNET; early onset; pancreatic cancer; survival

Mesh:

Year:  2016        PMID: 27416564     DOI: 10.1002/ijc.30273

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Poorly differentiated ductal adenocarcinoma of the pancreas with rapid progression in a young man.

Authors:  Koji Tezuka; Tomoharu Ishiyama; Akiko Takeshita; Hidekazu Matsumoto; Akira Jingu; Jiro Kikuchi; Hideyuki Yamaya; Rintaro Ohe; Tetsuya Ishizawa
Journal:  Clin J Gastroenterol       Date:  2018-04-16

2.  Bioinformatics analysis combined with experiments to explore potential prognostic factors for pancreatic cancer.

Authors:  Mu-Jing Ke; Lian-Dong Ji; Yi-Xiong Li
Journal:  Cancer Cell Int       Date:  2020-08-08       Impact factor: 5.722

3.  A Visualized Dynamic Prediction Model for Overall Survival in Elderly Patients With Pancreatic Cancer for Smart Medical Services.

Authors:  Jiang Zhong; XingShu Liao; Shuang Peng; Junyi Cao; Yue Liu; Chunyang Liu; Ju Qiu; Xiaoyan Guan; Yang Zhang; Xiaozhu Liu; Shengxian Peng
Journal:  Front Public Health       Date:  2022-05-24

4.  African-Americans and Indigenous Peoples Have Increased Burden of Diseases of the Exocrine Pancreas: A Systematic Review and Meta-Analysis.

Authors:  Aya Cervantes; Ellen K Waymouth; Maxim S Petrov
Journal:  Dig Dis Sci       Date:  2018-09-27       Impact factor: 3.199

5.  The clinical characteristics and survival associations of pancreatic neuroendocrine tumors: does age matter?

Authors:  Mengqi Liu; Xiaoyan Sun; Zheng Zhang; Xiaowu Xu; Xianjun Yu; Qifeng Zhuo; Shunrong Ji
Journal:  Gland Surg       Date:  2021-02

6.  Diabetes duration and weight loss are associated with onset age and remote metastasis of pancreatic cancer in patients with diabetes mellitus.

Authors:  Minglei Ma; Wei Li; Lingling Xu; Fan Ping; Huabing Zhang; Yuxiu Li
Journal:  J Diabetes       Date:  2022-02-15       Impact factor: 4.530

7.  Nomograms for predicting overall survival and cancer-specific survival in young patients with pancreatic cancer in the US based on the SEER database.

Authors:  Min Shi; Biao Zhou; Shu-Ping Yang
Journal:  PeerJ       Date:  2020-04-14       Impact factor: 2.984

8.  TMEFF2 inhibits pancreatic cancer cells proliferation, migration, and invasion by suppressing phosphorylation of the MAPK signaling pathway.

Authors:  Hongchao Han; Zhilin Zhan; Jie Xu; Zhenshun Song
Journal:  Onco Targets Ther       Date:  2019-12-23       Impact factor: 4.147

9.  Demographic, clinical, and pathological features of early onset pancreatic cancer patients.

Authors:  Chara Ntala; Silvana Debernardi; Roger M Feakins; Tatjana Crnogorac-Jurcevic
Journal:  BMC Gastroenterol       Date:  2018-09-12       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.